Definium's LSD-Based Pill Reduces Depression Symptoms in Late-Stage Trial

Definium Therapeutics announced that an LSD derivative pill significantly reduced depression symptoms in a late-stage clinical trial. The company stated that the drug showed promising results in treating major depressive disorder. The trial was conducted as placebo-controlled, and the drug's safety profile was assessed as positive. Analysts indicate that these results could strengthen Definium's position in the psychedelic-based treatment field. The company announced it will begin discussions with regulatory authorities to expedite the drug's licensing process. The need for new options in depression treatment highlights such innovative approaches. Definium emphasized that the drug's mechanism of action targets serotonin receptors in the brain, following a different pathway from traditional antidepressants. The company plans to publish detailed trial results in a medical journal soon. The market views this development as a positive catalyst for Definium's stock performance. This is not investment advice.